Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer

Published on Tuesday, 14 March 2017


Plasma melatonin concentrations were determined over a period of 24 hours in 20 women with clinical stage I or II breast cancer.

In ten of the patients, whose tumors were estrogen receptor positive, the nocturnal increase in plasma melatonin was much lower than that observed in eight control subjects.

Women with the lowest peak concentration of melatonin had tumors with the highest concentrations of estrogen receptors.

A significant correlation was found between the peak plasma melatonin concentration and the tumor estrogen receptor concentration in 19 of the patients.

These data suggest that low nocturnal melatonin concentrations may indicate the presence of estrogen receptor positive breast cancer and could conceivably have etiologic significance.



About this publication.


See also:

- About Melatonin;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonisn, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma.